Cantor Fitzgerald Maintains Neutral on Regeneron Pharmaceuticals, Lowers Price Target to $795
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Alethia Young has maintained a Neutral rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and lowered the price target from $815 to $795.
July 06, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Regeneron Pharmaceuticals' price target has been lowered from $815 to $795 by Cantor Fitzgerald, while maintaining a Neutral rating.
The lowering of the price target by Cantor Fitzgerald could potentially create a negative sentiment among investors. However, the maintained Neutral rating indicates that the analyst does not foresee a significant change in the stock's performance in the near term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100